Artal Participations S.a r.l.

CIK: 0002048403

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (25.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CAVA

CAVA GROUP, INC.

Director

LXRX

LEXICON PHARMACEUTICALS, INC.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (4 total)

CAVA
CAVA GROUP, INC.
Jun 15, 2026
Sale(S)
Direct
3M shares at avg. $90.30$270.9M
LXRX
LEXICON PHARMACEUTICALS, INC.
Apr 30, 2026
Exercise(M)
Indirect
20.4M shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Apr 30, 2026
Award(A)
Series B Convertible Preferred Stock
Indirect
408.4K shares-
LXRX
LEXICON PHARMACEUTICALS, INC.
Feb 17, 2026
Award(A)
Indirect
41.3K shares at avg. $65.00$2.7M

		Type	Shares	Price		Ownership
Jun 15, 2026	CAVA CAVA GROUP, INC.	Sale(S)	3,000,000	$90.30	$270,900,000	Direct
Apr 30, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Exercise(M)	20,421,735	-	$0	Indirect
Apr 30, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A) Series B Convertible Preferred Stock	408,435	-	-	Indirect
Feb 17, 2026	LXRX LEXICON PHARMACEUTICALS, INC.	Award(A)	41,290	$65.00	$2,683,823	Indirect

1-4 of 4 transactions

About Artal Participations S.a r.l.

Artal Participations S.a r.l. (SEC CIK 0002048403) files insider reports with the SEC as Director of CAVA GROUP, INC. (CAVA) and Director of LEXICON PHARMACEUTICALS, INC. (LXRX).

Signal8 holds 5 ownership filings by Artal Participations S.a r.l. (2 Form 3, 3 Form 4), filed between Dec 16, 2024 and Jun 17, 2026. Those filings report 4 transactions, from Feb 17, 2026 to Jun 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Artal Participations S.a r.l.'s filings is in LUXEMBOURG.

Recent filings by Artal Participations S.a r.l.

Jun 15, 2026: Open-market sale of CAVA shares (Form 4, code S).
Apr 30, 2026: Option exercise of LXRX shares (Form 4, code M).
Apr 30, 2026: Grant or award of LXRX derivative securities (Form 4, code A).
Feb 17, 2026: Grant or award of LXRX shares (Form 4, code A).

Other insiders filing for CAVA GROUP, INC. (CAVA)

KADOW JOSEPH JOHN, CLO & Secretary
Xenohristos Theodoros, Chief Concept Officer
Thompson Douglas W., Chief Operations Officer
Thomas Amiee Lynn, Director
Bosserman David, Director
SHAICH RONALD M, Director

How to read Form 4 transaction codes